Index - letter e

---

e-mail (ATN) 172

early intervention (WSJ92) 47

early intervention (ATN) 145

early intervention (PI) 134

early treatment (WSJ93) 101, 218, 223

East Germany (WSJ89) 368

echinacea (ATN) 12, 63, 69

education, computerized (WSJ88) 239

EEOC (WSJ93) 194

effects (WSJ87) 42, 244, 267, 271

effects (WSJ88) 69, 76, 152

effects (WSJ89) 87

effects (WSJ90) 10

eflornithine (WSJ86) 26

EICO (ATN) 138

elections (ATN) 211

Electric Windmill (WSJ88) 274

Elf Aquitaine (WSJ89) 101

Elizabeth Taylor (WSJ93) 234

Elizabeth Taylor (WSJ92) 364

Elyse Singer M.D. (ATN) 171

Emprise (ATN) 100

endocrine (ATN) 140, 150

Entertainment Weekly (WSJ92) 100

Enzo (WSJ91) 372, 384

enzyme (WSJ88) 78

enzyme Yale (WSJ92) 211

eosinophilic folliculitis (EF) (ATN) 161, 197

epidemic/pandemic (WSJ92) 24

epidemiology (ATN) 97, 151

Epitope (WSJ93) 55

Epitope (WSJ91) 172, 327

Epitope (WSJ92) 1, 14, 192, 399

EPO (erythropoietin) (ATN) 82, 150

epogen (WSJ91) 6

Epstein-Barr Virus (ATN) 93, 94

Erbamont (WSJ93) 85

Erisa (WSJ93) 64, 65

erythropoietin (EPO) (WSJ87) 124

erythropoietin (EPO) (WSJ88) 336

erythropoietin (EPO) (WSJ91) 2, 3, 266

erythropoietin (EPO) (ATN) 70, 82

erythropoietin (EPO) (PI) 126

Essex (WSJ88) 46

estate, real (WSJ87) 208

estate, real (WSJ91) 98

ethics (ATN) 208

ethyloxime 25 (ATN) 181

etiology origin (WSJ92) 278

etoposide (VP-16) (ATN) 73, 122, 149, 168

evaluating trials (PI) 77

exercise therapy (ATN) 157

expanded access (ATN) 212

expectancy (WSJ89) 71

exposure (WSJ85) 17, 19, 119, 164

exposure (WSJ87) 121, 164, 178, 186

exposure (WSJ88) 16, 124, 210, 353

exposure (WSJ89) 21, 33

exposure (biting) (WSJ86) 48

exposure (lawsuits) (WSJ87) 180, 247

exposure (lawsuits) (WSJ88) 404, 405

exposure (women) (WSJ86) 34

exposure (women) (WSJ88) 66